24.03.2014 21:45:00
|
U.S. Renal Care, Inc. -- Moody's rates U.S. Renal's incremental 1st lien term loan Ba3; downgrades 2nd lien term loan rating to Caa1 from B3; outlook remains negative.
New York, March 24, 2014 -- Moody's investors Service affirmed U.S. Renal Care, Inc.'s ("U.S. Renal") B2 Corporate Family Rating and B2-PD Probability of Default Rating. Concurrently, Moody's rated U.S. Renal's proposed $225 million incremental first lien term loan rating at Ba3. In addition, U.S. Renal's second lien term loan rating is lowered to Caa1 from B3 and the company's proposed $25 million add-on second lien term loan is rated Caa1. The outlook is negative.